Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TrippBio logo — Redefining Treatment for Respiratory Viruses

TrippBio

Redefining Treatment for Respiratory Viruses

6 employees Biotechnology, Pharmaceutical

General Information

Company Name TrippBio
Employees 6
Industries Biotechnology, Pharmaceutical
Social

Get notified when TrippBio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TrippBio

TrippBio, a biotech company, aims to redefine treatment for respiratory viruses including SARS-CoV-2, the virus responsible for COVID-19. The company's focus lies in identifying new applications for existing drugs to combat these viruses. With a primary emphasis on biotechnology and pharmaceuticals, TrippBio has positioned itself at the forefront of the battle against respiratory viruses. As of now, details regarding the founding date, headquarters location, and the most recent investment, including the investors and amount, are not available. However, the company's slogan, "Redefining Treatment for Respiratory Viruses," underscores its commitment to innovation in the field of virus treatment, making it a notable prospect for potential venture capital interest.

Taxonomy: Biotech, Drug Repurposing, Viral Treatment, Respiratory Diseases, Infectious Diseases, Pharmaceutical Research, Biomedical Innovation

No funding data available for TrippBio yet.

Get notified when TrippBio raises funding

TrippBio Alternatives & Competitors

TrippBio vs
Intercept Pharmaceuticals
Intercept Pharmaceuticals United States

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

Post Ipo Debt
376 employees
Biotechnology, Health Care
TrippBio vs
Vandria SA
Vandria SA Switzerland

We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic...

Grant
14 employees
Manufacturing, Pharmaceutical
TrippBio vs
CENSO BIOTECHNOLOGIES LTD
CENSO BIOTECHNOLOGIES LTD

A leading CRO with unparalleled expertise in intricate cell biology, focusing on human neurodegenera...

Series Unknown
1 employees
Biotechnology

FAQ About TrippBio

Redefining Treatment for Respiratory Viruses
TrippBio operates in the following industries: Biotechnology, Pharmaceutical.
TrippBio has approximately 6 employees.
Top alternatives and competitors to TrippBio include Intercept Pharmaceuticals, Vandria SA, CENSO BIOTECHNOLOGIES LTD, Rubedo Life Sciences, Antlia Bioscience, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TrippBio and Intercept Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TrippBio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes